GO
Loading...

Merck & Co Inc

More

  • NEW YORK, April 24- Healthcare companies on a seven-year tear have been top performers so far in 2015, helping to push broad stock indexes to record levels, but traders are now looking to protect themselves from a selloff as they await major earnings reports in the sector. Companies reporting first-quarter earnings next week include Bristol-Meyers Squibb Co,...

  • LONDON, April 24- European regulators have recommended approval of Bristol-Myers Squibb's Opdivo, paving the way for it to become the first of a closely watched group of immune system-boosting cancer medicines to go on sale in Europe. It competes with Merck& Co's Keytruda, which is also on the market in the United States but not in Europe. Although Keytruda is...

  • Business events scheduled for the coming week Thursday, 23 Apr 2015 | 1:43 PM ET

    Restaurant Brands International Inc. reports quarterly financial results before the market opens. WASHINGTON— Standard& Poor's releases S&P/Case-Shiller index of home prices for February, 9 a.m.; The Conference Board releases the Consumer Confidence Index for April, 10 a.m.; Federal Reserve policymakers meet to set interest rates. WASHINGTON— Commerce...

  • April 23- A unit of AstraZeneca Plc has teamed up with Juno Therapeutics Inc to develop combination treatments that use the body's immune system to kill cancer cells. The partnership between AstraZeneca's research and development arm MedImmune and Juno is the latest collaboration between companies intent on developing a new class of drugs known as...

  • Tekmira Ebola drug succeeds in small monkey study Wednesday, 22 Apr 2015 | 1:00 PM ET

    NEW YORK, April 22- An experimental Ebola drug from Tekmira Pharmaceuticals Corp cured all three monkeys intentionally infected with the virus, scientists reported on Wednesday, the first such success against the strain of Ebola in West Africa's 2014-2015 outbreak. Although other experimental treatments appeared to help Ebola patients last year,...

  • TRENTON, N.J.— One of the hot new cancer immunotherapy drugs, Merck& Co.' s Keytruda, strongly benefited patients with melanoma, lung cancer and mesothelioma, according to three studies presented Sunday at the American Association for Cancer Research conference in Philadelphia. One study, comparing Keytruda to Bristol-Myers Squibb Co.' s Yervoy, could give Merck...

  • April 17- A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against the most common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved lung cancer and melanoma indications. AstraZeneca Plc, Pfizer Inc and other drugmakers are developing their...

  • Big pharma M&A may keep booming, CEOs say Thursday, 16 Apr 2015 | 3:44 PM ET
    Generic copies of Merck & Co.'s cholesterol pill Zocor and Pfizer Inc.'s Zoloft antidepressant.

    For Pfizer and Merck, two big names that have ridden the merger wave, buying up more business is a possibility, their CEOs said.

  • Former Teva CEO's new gig at Ovid Therapeutics Thursday, 16 Apr 2015 | 6:10 AM ET

    After an abrupt departure, Former Teva CEO Jeremy Levin is now leading a start-up focused on rare neurological disorders.

  • LONDON, April 15- Having seen off a hostile $118 billion bid launched a year ago by U.S. rival Pfizer, Anglo-Swedish company AstraZeneca is on the move-- quite literally. Chief Executive Pascal Soriot is making AstraZeneca more nimble as hopes build for its cancer pipeline, but he still has his work cut out to keep 2015 earnings above the floor needed to protect his...

  • WASHINGTON, April 14- AstraZeneca Plc's diabetes drug Onglyza and Takeda Pharmaceutical Co.' s rival product Nesina should carry information about the risk of heart failure, an advisory committee to the U.S. Food and Drug Administration said on Tuesday. The panel reviewed safety data on AstraZeneca's Onglyza and Takeda's Nesina. The studies were requested by...

  • A preliminary FDA review of Nesina, or alogliptin, showed a numerical increase in heart failure hospitalizations but not a statistically significant increase. Even so, some analysts expect the FDA to treat all drugs in the class the same way. "We believe the FDA will likely view the risk as likely to be a class effect and apply changes to all approved drugs in the...

  • WASHINGTON, April 14- AstraZeneca Plc's diabetes drug Onglyza should include new safety information about the risk of heart failure, a U.S. Food and Drug Administration advisory panel concluded on Tuesday. The FDA is not obliged to follow the advice of its advisory panels but typically does so. A preliminary FDA review of the drug published on Friday noted an...

  • FDA panel wants heart failure risk on AstraZeneca drugs Tuesday, 14 Apr 2015 | 12:56 PM ET

    WASHINGTON— Federal health advisers say AstraZeneca's Onglyza and a related diabetes drug should carry new information about a possible association with heart failure and death. The FDA convened Tuesday's meeting to review data from a 16,000- patient study looking at Onglyza and Kombiglize's heart safety. AstraZeneca's study did not show links to heart...

  • Traders work the floor of the New York Stock Exchange.

    U.S. stocks closed higher, with the Dow above 18,000 for the first time in April as investors looked ahead to the official start of earnings season.

  • April 10- AstraZeneca Plc's diabetes drug Onglyza may be associated with an increased rate of death, according to a preliminary review of data by the U.S. Food and Drug Administration. The FDA's report, posted on the agency's website on Friday, comes ahead of an April 14 meeting of an FDA advisory panel to discuss the drug's safety. The FDA said the causes of death...

  • *Index Ventures clocks up 11 transactions since 2005. Ten years on from pioneering an ultra-lean business model focused on investing in "virtual" companies with a single experimental medicine, XO1's backer Index Ventures is chalking up some notable wins. The new model has grabbed attention as venture capitalists strive to improve returns in a notoriously...

  • Early movers: RDSA, TSLA, MRK, RAD & more Wednesday, 8 Apr 2015 | 8:02 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Traders work the floor of the New York Stock Exchange.

    U.S. stocks closed higher, rebounding from initial losses on the disappointing jobs report as weak data renewed hopes of a rate hike delay.

  • Biotech wins $45 million grant for Ebola vaccine Monday, 6 Apr 2015 | 9:28 AM ET
    Dr. Joseph Kim, founder of Inovio Pharmaceuticals

    Today's vaccine debate will be outdated if Inovio succeeds in developing DNA vaccines. Imagine a single needle shot that can cure Ebola.